Skip to main content

Immunome Inc 10-Q for FY2026 Q3

Immunome Inc. (IMNM)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Immunome Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Immunome Inc. reported positive Phase 3 RINGSIDE results for varegacestat and said the FDA accepted its NDA, assigning a PDUFA target action date of April 28, 2027. The company has generated no product-sales revenue. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $0 a year earlier
Net loss
$85.78M
compared with a net loss of $57.46M a year earlier
Diluted EPS
-$0.76
compared with -$0.65 a year earlier